Metastatic phenotype in CWR22 XXXX xenograft following castration.

@entity1 @entity263 @entity19 @entity5 @entity342 @entity3
BACKGROUND: CWR22 is a @entity1 xenograft model of @entity263 ( @entity263 ) that is often utilized to study castration recurrent (CR) @entity263 . CWR22 recapitulates clinical response to @entity342 deprivation therapy (ADT), in that @entity5 regress in response to castration, but can recur after a period of time. METHODS: Two cohorts of @entity19 , totaling 117 @entity19 were implanted with CWR22, allowed to develop @entity5 , castrated by pellet removal and followed for a period of 32 and 50 weeks. @entity19 presenting with @entity5 >2.0   cm(3) at the primary site, moribund appearance, or palpable masses other than the primary @entity5 were sacrificed prior to the endpoint of the study. Tumor tissue, serum, and abnormal lesions were collected upon necropsy and analyzed by IHC, H_E, and PCR for presence of metastatic lesions arising from CWR22. RESULTS: Herein, we report that CWR22 progresses after castration from a primary, hormonal therapy-na  ve @entity5 to @entity3 in 20% of castrated @entity19 . Histological examination of CWR22 @entity5 revealed distinct pathologies that correlated with metastatic outcome after castration. CONCLUSION: This is the first report and characterization of spontaneous @entity3 in the CWR22 model, thus, CWR22 is a bona-fide model of clinical @entity263 representing the full progression from @entity342 -sensitive, primary @entity263 to metastatic CR- @entity263 . Prostate 76:359-368, 2016.    2015 The Authors. The Prostate published by Wiley Periodicals, Inc.
